Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LYL 845

Next Previous
X
Search
Drug Profile

LYL 845

Alternative Names: LYL-845

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyell Immunopharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Feb 2024 LYL 845 receives Orphan Drug status for Malignant melanoma (Late-stage disease) in USA
  • 21 Dec 2022 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (Parenteral) (NCT05573035)
  • 21 Dec 2022 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Refractory metastatic disease) in USA (Parenteral) (NCT05573035)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top